![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](/content/dam/biopharm/esperoct/global/esperoct-logo.png){kind=logo}
Your approach to treating hemophilia A can vary based on your personality. Take our 5-question quiz to discover your “treatment personality” type—and unlock insights to help you get the most out of your therapy.
Ask your doctor about a switch to Esperoct®.
Experience the Esperoct® difference–with less frequent dosing and higher factor levels compared with standard half-life products.
Esperoct® is designed to provide high factor levels and proven protection from bleeds compared with standard half-life products.
aTrough level goal is 1% for prophylaxis.
bData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18years) were 2.7 IU/dL.
cSteady-state factor VIII (FVIII) activity levels were estimated in 143 adults and adolescents using PK modeling.
Are you a Commander or an Investigator?
Learn more about your treatment personality type.
Are you a Commander or an Investigator?
Learn more about your treatment personality type.
Your approach to treating hemophilia A can vary based on your personality. Take our 5-question quiz to discover your “treatment personality” type—and unlock insights to help you get the most out of your therapy.
Switch to fewer infusions.
Compared with standard half-life dosing schedules, the simple, fixed dosing routine of Esperoct® calls for fewer infusions per year.
No dose adjustment needed
If you previously infused every other day
If you previously infused 3x/week
No dose adjustment needed.d
If your child previously infused every other day
If your child previously infused 3x/week
dInterval can be adjusted based on individual response to treatment.
Where can Esperoct® take you?
Even parts of Alaska reach summer temps above 90°F. Esperoct® is the only EHL product that can be stored from 86°F up to 104°F for up to 3 months. Wherever you go, Esperoct® can take the heat.
Connect with your HCL.
Questions about switching to Esperoct®? Connect with your Hemophilia Community Liaison (HCL) for personalized support in your journey with hemophilia A. Find your HCL now.
Your questions, answered.
Question: What is a trough level?
Answer: Factor in the bloodstream rises and falls in patients treated prophylactically with factor. It is highest right after an infusion and lowest right before an infusion. The low level right before infusion is called the trough level. Many factor products aim to keep trough levels at 1%. In a study of adults and adolescents who were treated with Esperoct® for prophylaxis, researchers found that extended half-life Esperoct® keeps trough levels at or above 3% (moderate hemophilia) all of the time, and 5% (mild hemophilia) approximately 90% of the time, based on PK modeling.e,f,g
Question: Why is knowing a product’s half-life important?
Answer: Measuring a factor’s half-life gives doctors, patients and caregivers the opportunity to compare the factor activity level of different products by calculating the time it takes the body to metabolize or inactivate half the amount of factor.
How long factor stays in the blood, however, is only half the battle. The other consideration is the factor level. The extended half-life of Esperoct® (22 hours on average in adults) offers higher factor levels for longer compared to standard half-life products.h
eTrough level goal is 1% for prophylaxis.
fData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
gSteady-state factor VIII (FVIII) activity levels were estimated in 143 adults and adolescents using PK modeling.
hData shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.